Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913125 | 0.95 | PDE4B (0.52) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL14225752 | 0.93 | PDE4B (0.53) | PDE4BMAPTHDAC1HDAC2HDAC3 | |
| SCHEMBL25202320 | 0.92 | PDE4B (0.59) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL12479918 | 0.85 | NAMPT (0.52) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL30778326 | 0.85 | NAMPT (0.54) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL15157112 | 0.85 | NAMPT (0.54) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL14225756 | 0.84 | PDE4B (0.53) | PDE4BMAPTHDAC1HDAC2HDAC3 | |
| SCHEMBL25539754 | 0.84 | PDE4B (0.53) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL9962347 | 0.84 | PDE4B (0.54) | PDE4BKDM4EMAPTTHRBHDAC1 | |
| SCHEMBL25203147 | 0.83 | NAMPT (0.56) | PDE4BNAMPTKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-09-19 | — | — | US | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | CSF1R, CSF3R, IL15RA | PDE4B 324/4885NAMPT 2030/4885KDM4E 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.